Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
Status:
Completed
Trial end date:
2018-08-21
Target enrollment:
Participant gender:
Summary
This study will examine the efficacy of omarigliptin 25 mg once weekly compared to placebo in
Japanese patients with T2DM who have inadequate glycemic control on insulin monotherapy in
addition to diet and exercise therapy. The primary hypothesis of the study is that
omarigliptin 25 mg once weekly provides greater reduction in hemoglobin A1C (HbA1c) compared
with placebo as assessed by change from baseline to Week 16 [Phase A (double-blind period)].